Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib in Children With Severe Neurofibromatosis Type 2
2024-516607-16-00Phase 2Authorised
- Sponsor
- Medical University of Warsaw
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of crizotinib in neurofibromatosis type 2 (NF2), sponsored by Medical University of Warsaw. Primary endpoint: Stabilization or regression of the primary tumor. Planned start Aug 2024; status: authorised.
02
Drugs
crizotinib
03
Conditions
neurofibromatosis type 2 (NF2)
Beyond the preview
Go deeper on 2024-516607-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516607-16-00.